Neurocrine Biosciences (NASDAQ:NBIX) Insider Darin Lippoldt Sells 10,000 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Darin Lippoldt sold 10,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $179.60, for a total transaction of $1,796,000.00. Following the completion of the transaction, the insider owned 54,729 shares of the company’s stock, valued at $9,829,328.40. This trade represents a 15.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Darin Lippoldt also recently made the following trade(s):

Get Neurocrine Biosciences alerts:

• On Monday, June 29th, Darin Lippoldt sold 9,800 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $170.16, for a total transaction of $1,667,568.00.
• On Friday, June 26th, Darin Lippoldt sold 200 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $169.56, for a total transaction of $33,912.00.

Neurocrine Biosciences Trading Down 1.8%

Shares of NBIX stock traded down $3.12 during midday trading on Monday, reaching $173.99. 1,573,039 shares of the stock were exchanged, compared to its average volume of 1,184,527. Neurocrine Biosciences, Inc. has a 1 year low of $122.14 and a 1 year high of $181.18. The company’s 50 day moving average is $160.84 and its two-hundred day moving average is $142.87. The firm has a market cap of $17.49 billion, a PE ratio of 26.81, a price-to-earnings-growth ratio of 0.71 and a beta of 0.39.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Piper Sandler upped their price target on Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. HC Wainwright raised their price objective on Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 25th. Citigroup upped their target price on shares of Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, Canaccord Genuity Group increased their price target on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $191.67.

Read Our Latest Research Report on NBIX

Institutional Trading of Neurocrine Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in NBIX. USA Financial Formulas purchased a new position in Neurocrine Biosciences during the fourth quarter valued at $25,000. Geneos Wealth Management Inc. grew its stake in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the last quarter. DJE Kapital AG purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter worth $28,000. Basecamp Wealth Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after acquiring an additional 204 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC bought a new position in shares of Neurocrine Biosciences during the first quarter valued at $33,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

Featured Articles

• Five stocks we like better than Neurocrine Biosciences
• The SK Hynix IPO and 2027’s AI Memory Squeeze
• Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
• Why Welltower’s Growth Story Might Outrun Its Rich Valuation
• One Short- and One Long-Term ETF for Quantum Computing Bulls

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.